The Changing Face of Innovation in Drug Discovery

Emma Greenwood, Telomerase — the third element? Nature Reviews Cancer. ,vol. 3, pp. 7- 7 ,(2003) , 10.1038/NRC978

Ana Sofia Pina, Abid Hussain, Ana Cecília A. Roque, An historical overview of drug discovery. Methods of Molecular Biology. ,vol. 572, pp. 3- 12 ,(2010) , 10.1007/978-1-60761-244-5_1

Robert A. Blake, Target validation in drug discovery. Methods of Molecular Biology. ,vol. 356, pp. 367- 377 ,(2007) , 10.1385/1-59745-217-3:367

Jaye Chin-Dusting, Jacques Mizrahi, Garry Jennings, Desmond Fitzgerald, Finding improved medicines: the role of academic|[ndash]|industrial collaboration Nature Reviews Drug Discovery. ,vol. 4, pp. 891- 897 ,(2005) , 10.1038/NRD1879

Steven K. Hanks, Tony Hunter, Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. The FASEB Journal. ,vol. 9, pp. 576- 596 ,(1995) , 10.1096/FASEBJ.9.8.7768349

Ismail Kola, John Landis, Can the pharmaceutical industry reduce attrition rates? Nature Reviews Drug Discovery. ,vol. 3, pp. 711- 716 ,(2004) , 10.1038/NRD1470

Mark Reimers, Statistical analysis of microarray data. Addiction Biology. ,vol. 10, pp. 23- 35 ,(2005) , 10.1080/13556210412331327795

Litao Zhang, Mary Ellen Cvijic, Jonathan Lippy, James Myslik, Stephen L. Brenner, Alastair Binnie, John G. Houston, Case study: technology initiative led to advanced lead optimization screening processes at Bristol-Myers Squibb, 2004–2009 Drug Discovery Today. ,vol. 17, pp. 733- 740 ,(2012) , 10.1016/J.DRUDIS.2012.02.012

Philip Cohen, Dario R. Alessi, Kinase Drug Discovery – What’s Next in the Field? ACS Chemical Biology. ,vol. 8, pp. 96- 104 ,(2013) , 10.1021/CB300610S

John P. Overington, Bissan Al-Lazikani, Andrew L. Hopkins, How many drug targets are there Nature Reviews Drug Discovery. ,vol. 5, pp. 993- 996 ,(2006) , 10.1038/NRD2199